Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in: Current Bladder Dysfunction Reports 2/2012

01.06.2012 | Neurogenic Bladder (F Daneshgari, Section Editor)

Neurogenic Bladder in Pediatrics and Adolescents

verfasst von: Peter P. Stuhldreher, Edward E. Cherullo, Robert Kohut

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Neurogenic bladder in the pediatric population underwent an evolution in treatment patterns during the 20th century. This paradigm change began with an evolving understanding of the health risks children with this condition face and the variable pathophysiology resulting in their condition. Introduction of clean intermittent catheterization and anticholinergic medication revolutionized care of these young patients. Advances in our knowledge of bladder pathology, and novel techniques to improve lower urinary tract function have made a variety of treatments available to patients. Although some similarities exist between adult and pediatric neurogenic bladder, the pediatric patient provides unique challenges with growth and development and helping children gain independence. Presented is a review of the treatment options and an algorithm to support the two main goals of treatment: protection of the upper urinary tract from renal function deterioration and development of social continence.
Literatur
1.
Thompson DNP. Spinal dysraphic anomalies; classification, presentation and management. Paediatr Child Health. 2010;20(9):397–403.CrossRef
2.
Abrahamsson K, Olsson I, Sillén U. Urodynamic findings in children with myelomeningocele after untethering of the spinal cord. J Urol. 2007;177(1):331–4.PubMedCrossRef
3.
Kaefer M, Pabby A, Kelly M, Darbey M, Bauer SB. Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomeningocele. J Urol. 1999;162:1068–71.PubMedCrossRef
4.
Generao SE, Dall’Era JP, Stone AR, Kurzrock EA. Spinal cord injury in children: long-term urodynamic and urological outcomes. J Urol. 2004;172(3):1092–4.PubMedCrossRef
5.
6.
Silveri M, Salsano L, Pierro MM, Mosiello G, Capitanucci ML, De Gennaro M. Pediatric spinal cord injury: approach for urological rehabilitation and treatment. J Pediatr Urol. 2006;2(1):10–5.PubMedCrossRef
7.
Tanaka ST, Stone AR, Kurzrock EA. Transverse myelitis in children: long-term urological outcomes. J Urol. 2006;175(5):1865–8.PubMedCrossRef
8.
Decter RM, Bauer SB, Khoshbin S, et al. Urodynamic assessment of children with cerebral palsy. J Urol. 1987;138(4 Pt 2):1110–2.PubMed
9.
Morrisroe SN, O’Connor RC, Nanigian DK, Kurzrock EA, Stone AR. Vesicostomy revisited: the best treatment for the hostile bladder in myelodysplastic children? BJU Int. 2005;96(3):397–400.PubMedCrossRef
10.
Lapides J, Diokno AC, Silber SM, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol. 1972;107:458–61.PubMed
11.
Anagnostopoulos D, Joannides E, Kotsianos K. The urological management of patients with myelodysplasia. Pediatr Surg Int. 1988;3:347–50.CrossRef
12.
Holzbeierlein J, Pope JC, Adams MC, Bruner J, Tylipan N, Brock JW. The urodynamic profile of myelodysplasia in childhood with spinal closure during gestation. J Urol. 2000;164:1336–9.PubMedCrossRef
13.
Edelstein RA, Bauer SB, Kelly M, et al. The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy. J Urol. 1995;154:1500–4.PubMedCrossRef
14.
Klose A, Sackett C, Mesrobian H. Management of children with myelodysplasia: urological alternatives. J Urol. 1990;144:1446–9.PubMed
15.
Tanaka H, Kazizaki H, Kobayashi S, Shibata T, Ameda K, Koyanagi T. The relevance of urethral resistance in children with myelodysplasia: its impact on upper urinary tract deterioration and the outcome of conservative management. J Urol. 1999;161:929–32.PubMedCrossRef
16.
McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;126:205–9.PubMed
17.
Palmer LS, Richards I, Kaplan W. Age related bladder capacity and bladder capacity growth in children with myelomeningocele. J Urol. 1997;158:1261–4.PubMedCrossRef
18.
Painter KA, Vates TS, Bukowski TP, et al. Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia. J Urol. 1996;156:1459–62.PubMedCrossRef
19.
Palmer LS, Zebold K, Firlit CF, Kaplan WE. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. J Urol. 1997;157:638–40.PubMedCrossRef
20.
Altaweel W, Jednack R, Bilodeau C, Corcos J. Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol. 2006;175(3):1102–5.PubMedCrossRef
21.
22.
Pascali MP, Mosiello G, Boldrini R, Salsano ML, Castelli E, De Gennaro M. Effects of botulinum toxin Type A in the bladder wall of children with neurogenic bladder dysfunction: a comparison of histological features before and after injections. J Urol. 2011;185(6):2552–7.PubMedCrossRef
23.
Hoebeke P, De Caestecker K, Vande Walle J, et al. The effect of botulinum-A toxin in Incontinent children with therapy resistant overactive detrusor. J Urol. 2006;176(1):328–31.PubMedCrossRef
24.
Schulte-Baukloh H, Michael T, Stürzebecher B, Knispel HH. Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol. 2003;44(1):139–43.PubMedCrossRef
25.
• De Gennaro M, Capitanucci ML, Mosiello G, Zaccara A. Current state of nerve stimulation technique for lower urinary tract dysfunction in children. J Urol. 2011;185(5):1571–7. This study gives an excellent review of data behind nerve stimulation in children, and future directions in research.PubMedCrossRef
26.
• Clark C, Ngo T, Comiter CV, Anderson R, Kennedy W. Sacral nerve stimulator revision due to somatic growth. J Urol. 2011;186(4):1576–80. This study provides an example of the data needed in the pediatric population regarding nerve stimulation. Though it is a very small sample size, this helps build knowledge and efficacy data on the use of sacral stimulation.PubMedCrossRef
27.
Quek ML, Ginsberg DA. Long-term urodynamics followup of bladder augmentation for neurogenic bladder. J Urol. 2003;169:195–8.PubMedCrossRef
28.
Medel R, Ruarte AC, Herrera M, Castera R, Podesta ML. Urinary continence outcome after augmentation ileocystoplasty as a single surgical procedure in patients with myelodysplasia. J Urol. 2002;168:1849–52.PubMedCrossRef
29.
DeFoor W, Minevich E, Reddy P, et al. Bladder calculi after augmentation cystoplasty: risk factors and prevention strategies. J Urol. 2004;172(5):1964–6.PubMedCrossRef
30.
Leyland JW, Masters JG. Conservative management of an intraperitoneal rupture of an augmentation cystoplasty and continent urinary diversion in an adult. J Urol. 2003;170(2):524.PubMedCrossRef
31.
Soergel TM, Cain MP, Misseri R, Gardner TA, Koch MO, Rink RC. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol. 2004;172(4):1649–52.PubMedCrossRef
32.
• Kokorowski PJ, Routh JC, Borer JG, Estrada CR, Bauer SB, Nelson CP. Screening for malignancy after augmentation cystoplasty in children with spina bifida: a decision analysis. J Urol. 2011;186(4):1437–43. This study gives a good, realistic approach to screening for patients after augmentation. It provides support that patients should be counseled preoperatively about a small risk of malignancy.PubMedCrossRef
33.
Sundaram CP, Reinberg Y, Aliabadi HA. Failure to obtain durable results with collagen implantation in children with urinary incontinence. J Urol. 1997;157:2306–7.PubMedCrossRef
34.
Austin PF, Westney OL, Leng WW, McGuire EJ, Ritchey M. Advantages of rectus fascial slings for uinary incontinence in children with neuropathic bladder. J Urol. 2001;165:2369–72.PubMedCrossRef
35.
Castera R, Podesta ML, Ruarte AC, Herrera M, Medel R. 10-year experience with artificial urinary sphincter in children and adolescents. J Urol. 2001;165:2373–6.PubMedCrossRef
36.
Hajlvassilou CA. A review of the complications and results of implantation of the AMS artificial urinary sphincter. Eur Urol. 1999;35(1):36–44.CrossRef
37.
Holmes NM, Kogan BA, Baskin LS. Placement of artificial urinary sphincter in children and simultaneous gastrocystoplasty. J Urol. 2001;165:2366–8.PubMedCrossRef
38.
Catto J, Natarajan V, Tophill P. Simultaneous augmentation cystoplasty is associated with earlier rather than increased artificial urinary sphincter infection. J Urol. 2005;173(4):1237–41.PubMedCrossRef
Metadaten
Titel
Neurogenic Bladder in Pediatrics and Adolescents
verfasst von
Peter P. Stuhldreher
Edward E. Cherullo
Robert Kohut
Publikationsdatum
01.06.2012
Verlag
Current Science Inc.
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 2/2012
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-012-0131-1

Weitere Artikel der Ausgabe 2/2012

Current Bladder Dysfunction Reports 2/2012 Zur Ausgabe

Neurogenic Bladder (F Daneshgari, Section Editor)

Surgical Options for Patients with Neurogenic Bladder

Infectious Bladder Dysfunction (MS Mourad, Section Editor)

HIV-Induced Cystopathy

Infectious Bladder Dysfunction (MS Mourad, Section Editor)

Complications of Chronic Prostatitis

Infectious Bladder Dysfunction (MS Mourad, Section Editor)

Tuberculous Cystitis

Neurogenic Bladder (F Daneshgari, Section Editor)

Lower Urinary Tract Dysfunction in Multiple Sclerosis

Infectious Bladder Dysfunction (MS Mourad, Section Editor)

GAG Layer Replenishment Therapy for Recurrent Infectious Bladder Dysfunction

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise